Cephalon, Inc. (Nasdaq: CEPH) confirmed that an FDA panel voted not to recommend approval of an expanded ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE